Table 2 Association of MACC1 expression in the tumor front and tumor buds with clinicopathological data
Characteristics | MACC1 tumor front N (%); (n = 187) | P-value | MACC1 tumor buds N (%); (n = 187) | P-value | ||
|---|---|---|---|---|---|---|
|  | Low (Score 0) | High (Score 1–3) |  | Low (<median) | High (>median) |  |
Age (yrs.) | ||||||
Mean (min, max) | 69.9 (38–88) | 68.1 (35–93) | 0.1141 | 70.1 (36–89) | 67.6 (41–91) | 0.0408 |
Tumor size (cm) | ||||||
Mean (min, max) | 5.0 (2–12) | 4.4 (1.2–8.0) | 0.4457 | 4.6 (2–12) | 4.5 (1.2–8) | 0.7134 |
Gender | ||||||
Male | 18 (35.3) | 70 (51.9) | 0.0436 | 23 (46.0) | 32 (45.1) | 0.9195 |
Female | 33 (64.7) | 65 (48.2) | Â | 27 (54.0) | 39 (54.9) | Â |
Histological subtype | ||||||
Non-mucinous | 46 (90.2) | 121 (89.0) | 0.8092 | 45 (90.0) | 61 (85.9) | 0.502 |
Mucinous | 5 (9.8) | 15 (11.0) | Â | 5 (10.0) | 10 (14.1) | Â |
Tumor grade | ||||||
G1-2 | 36 (70.6) | 84 (61.8) | 0.2624 | 30 (60.0) | 35 (49.3) | 0.2449 |
G3 | 15 (29.4) | 52 (38.2) | Â | 20 (40.0) | 36 (50.7) | Â |
Tumor location | ||||||
Left | 27 (52.9) | 86 (63.7) | 0.3547 | 30 (60.0) | 43 (61.4) | 0.7867 |
Rectum | 6 (11.8) | 15 (11.1) | Â | 7 (14.0) | 7 (10.0) | Â |
Right | 18 (35.3) | 34 (25.2) | Â | 13 (26.0) | 20 (28.6) | Â |
pT | ||||||
pT1 + pT2 | 22 (43.1) | 25 (18.4) | 0.0005 | 15 (30.0) | 3 (4.2) | <0.0001 |
pT3 + pT4 | 29 (56.9) | 111 (81.6) |  | 35 (70.0) | 68 (95.8) |  |
pN | ||||||
pN0 | 38 (74.5) | 59 (43.4) | 0.0001 | 26 (52.0) | 24 (33.8) | 0.0453 |
pN1-2 | 13 (25.5) | 77 (56.6) | Â | 24 (48.0) | 47 (66.2) | Â |
pM | ||||||
pM0 | 50 (98.0) | 117 (86.7) | 0.0223 | 47 (94.0) | 60 (85.7) | 0.1499 |
pM1 | 1 (2.0) | 18 (13.3) | Â | 3 (6.0) | 10 (14.3) | Â |
TNM stage | ||||||
Stage I | 22 (43.1) | 18 (13.3) | <0.0001 | 13 (26.0) | 1 (1.4) | 0.0004 |
Stage II | 15 (29.4) | 38 (282.) | Â | 12 (24.0) | 20 (28.6) | Â |
Stage III | 13 (25.5) | 61 (45.2) | Â | 22 (44.0) | 39 (55.7) | Â |
Stage IV | 1 (2.0) | 18 (13.3) | Â | 3 (6.0) | 10 (14.3) | Â |
Tumor budding | ||||||
Low-grade | 38 (74.5) | 63 (46.3) | 0.0006 | 28 (56.0) | 20 (28.2) | 0.0021 |
High-grade | 13 (25.5) | 73 (53.7) | Â | 22 (44.0) | 51 (71.8) | Â |
Venous invasion | ||||||
Present | 3 (5.9) | 29 (21.3) | 0.0125 | 7 (14.0) | 19 (26.8) | 0.0924 |
Absent | 48 (94.1) | 107 (78.7) | Â | 43 (86.0) | 52 (73.2) | Â |
Lymphatic invasion | ||||||
Present | 11 (21.6) | 63 (46.3) | 0.002 | 24 (48.0) | 38 (53.5) | 0.5496 |
Absent | 40 (78.4) | 73 (53.7) | Â | 26 (52.0) | 33 (46.5) | Â |
Therapy | ||||||
Untreated | 29 (56.9) | 37 (27.2) | 0.0002 | 24 (48.0) | 9 (12.7) | <0.0001 |
Treated | 22 (43.1) | 99 (72.8) | Â | 26 (52.0) | 62 (87.3) | Â |
MMR status | ||||||
Proficient | 44 (86.3) | 126 (93.3) | 0.1256 | 46 (92.0) | 63 (90.0) | 0.7607 |
Deficient | 7 (13.7) | 9 (6.7) | Â | 4 (8.0) | 7 (10.0) | Â |
KRAS status | ||||||
Wild-type | 32 (64.0) | 92 (68.2) | 0.594 | 33 (66.0) | 46 (65.7) | 0.974 |
Mutation | 18 (36.0) | 43 (31.9) | Â | 17 (34.0) | 24 (34.3) | Â |
BRAF status | ||||||
Wild-type | 45 (90.0) | 120 (91.6) | 0.772 | 44 (89.8) | 60 (89.6) | 0.966 |
Mutation | 5 (10.0) | 11 (8.4) | Â | 5 (10.2) | 7 (10.5) | Â |
CIMP status | ||||||
Negative/Low | 27 (90.0) | 63 (86.3) | 0.7514 | 21 (84.0) | 36 (83.7) | 1.0 |
High | 3 (10.0) | 10 (13.7) | Â | 4 (16.0) | 7 (16.3) | Â |
Survival rate | ||||||
Median | Not reached | 58 (43-ne) | 0.0217 | 53.0 (43–61) | 55.0 (36-ne) | 0.839 |